FDA Requires More Data on Merck's COVID-19 Drug
[unable to retrieve full-text content]
Merck & Co said Thursday that U.S. regulators have asked for additional data beyond the Phase III study already conducted in order to support potential emergency use authorization of its experimental COVID-19 drug MK-7110.
Advertising by Adpathway




